AEON Biopharma, Inc. completed an underwritten public offering on July 15, 2026, consisting of 17,851,599 shares of Class A common stock and 24,837,008 pre-funded warrants, plus an over-allotment of 6,403,290 shares/warrants exercised by the representative. The offering included two-year and five-year milestone warrants tied to regulatory and clinical developments for ABP-450. The company received approximately $12.2 million in net proceeds, with gross proceeds from the initial offering expected at $13.75 million. Potential additional gross proceeds of up to $29.6 million could be realized through the cash exercise of milestone warrants. Net proceeds are intended for working capital and comparative analytical testing of ABP-450 to support biosimilarity to BOTOX®. AEON Biopharma is a biopharmaceutical company developing biosimilar products.
